DOI: 10.1542/peds.2004-1178 2005;115;1529Pediatrics Martano and Firmino F. Rubaltelli Carlo Dani, Giovanna Bertini, Marco Pezzati, Chiara Poggi, Pietro Guerrini, Claudio Among Preterm Infants: A Multicenter, Randomized Study Prophylactic Ibuprofen for the Prevention of Intraventricular Hemorrhage http://pediatrics.aappublications.org/content/115/6/1529.full.html located on the World Wide Web at: The online version of this article, along with updated information and services, is of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275. Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2005 by the American Academy published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point publication, it has been published continuously since 1948. PEDIATRICS is owned, PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from Prophylactic Ibuprofen for the Prevention of Intraventricular Hemorrhage Among Preterm Infants: A Multicenter, Randomized Study Carlo Dani, MD*; Giovanna Bertini, MD*; Marco Pezzati, MD*; Chiara Poggi, MD*; Pietro Guerrini, MD‡; Claudio Martano, MD§; Firmino F. Rubaltelli, MD*; and the IntraVentricular Ibuprofen Study Group ABSTRACT. Objective. Ibuprofen enhances cerebral blood flow autoregulation and was shown to protect neurologic functions after oxidative stresses in an animal model. For these reasons, we hypothesized that the pro- phylactic use of ibuprofen would reduce the occurrence of intraventricular hemorrhage (IVH) and its worsening toward grades 2 to 4 among preterm infants. To confirm this hypothesis, we planned the present prospective study. Methods. This was a double-blind, randomized, con- trolled trial in which preterm infants with gestational ages of <28 weeks received ibuprofen or placebo within the first 6 hours of life. The infants were assigned ran- domly, at 7 neonatal care units, to receive ibuprofen (10 mg/kg, followed by 5 mg/kg after 24 and 48 hours) or placebo. Serial echoencephalography was performed 24 and 48 hours after the initial cerebral ultrasound study, on postnatal days 7, 15, and 30, and at 40 weeks’ postcon- ceptional age. Grade 1 IVH or no IVH was considered a successful outcome, whereas grade 2 to 4 IVH repre- sented failure. The rates of ductal closure, side effects, and complications were recorded. Results. We studied 155 infants. Grade 2 to 4 IVH developed for 16% of the ibuprofen-treated infants and 13% of the infants in the placebo group. The occurrence of patent ductus arteriosus was less frequent only on day 3 of life in the ibuprofen group. There were no signifi- cant differences with respect to other complications or adverse effects. Conclusions. Our study demonstrated that prophylac- tic ibuprofen is ineffective in preventing grade 2 to 4 IVH and that its use for this indication cannot be recommended. Pediatrics 2005;115:1529–1535; ibuprofen, intraventricular hemorrhage, patent ductus arteriosus, infants. ABBREVIATIONS. IVH, intraventricular hemorrhage; PDA, patent ductus arteriosus; CBF, cerebral blood flow; iRDS, infant respiratory distress syndrome; ROP, retinopathy of prematurity; OR, odds ratio; CI, confidence interval; PVL, periventricular leukomalacia; PPHN, persistent pulmonary hypertension of the newborn. D espite improvements in the assistance and treatment of preterm infants, intraventricular hemorrhage (IVH) remains a frequent com- plication among these patients. 1 This point is crucial because the most severe IVH cases are related to a high risk of neurodevelopmental handicaps. In fact, mental retardation, seizures, and cerebral palsy have been reported for 45% to 86% of preterm infants with parenchymal IVH involvement. 2–5 Previous clinical trials demonstrated that indo- methacin, a cyclooxygenase inhibitor of prostaglan- din synthesis that is used commonly for the closure of patent ductus arteriosus (PDA), decreased the in- cidence of IVH among very low birth weight in- fants. 6–10 Indomethacin was shown to decrease base- line cerebral blood flow (CBF), to modulate CBF changes in response to hypercarbic insults, to de- crease serum prostaglandin levels, and to promote germinal matrix maturation in animal models. 11–14 However, indomethacin prophylaxis for IVH has never been used widely, because of the adverse ef- fects of indomethacin on renal function and the gas- trointestinal tract. 10,15–19 In contrast, experimental 20 and preliminary clini- cal 21–24 studies demonstrated that ibuprofen (another cyclooxygenase inhibitor of prostaglandin synthesis) was effective in closing PDA without reducing CBF 25 or affecting cerebral vasoreactivity to arterial carbon dioxide tension 26 or intestinal 27,28 or renal 29 hemody- namics. Furthermore, ibuprofen enhances CBF auto- regulation 30 and was shown to protect neurologic functions after oxidative stresses in an animal mod- el. 31 For these reasons, we hypothesized that the pro- phylactic use of ibuprofen would reduce the occur- rence of IVH and its worsening toward grades 2 to 4 among preterm infants. To confirm this hypothesis, we planned a double-blind, randomized, controlled trial in which preterm infants with gestational age of Ͻ28 weeks received ibuprofen or placebo within the first 6 hours of life. METHODS Patient Population A multicenter, double-blind, prospective study, approved by local ethics committees, was conducted in 7 tertiary neonatal care units (Careggi University Hospital of Florence, Sant’Anna Univer- sity Hospital of Ferrara, Clinica Mangiagalli of Milan, Children’s Hospital “V. Buzzi” of Milan, San Gerardo Hospital of Monza, Regional Hospital of Bolzano, and Sant’Anna Hospital of Turin, all in Italy). Inclusion criteria were gestational age of Ͻ28 weeks From the *Department of Surgical and Medical Critical Care, Section of Neonatology, Careggi University Hospital of Florence, Florence, Italy; ‡Di- vision of Neonatology, Sant’Anna University Hospital of Ferrara, Ferrara, Italy; and §Division of Neonatology, Sant’Anna University Hospital of Turin, Turin, Italy. Accepted for publication Oct 4, 2004. doi:10.1542/peds.2004-1178 No conflict of interest declared. Reprint requests to (C.D.) Division of Neonatology, Careggi University Hospital, University of Florence School of Medicine, Viale Morgagni, 85 Firenze, Italy. E-mail: cdani@unifi.it PEDIATRICS (ISSN 0031 4005). Copyright © 2005 by the American Acad- emy of Pediatrics. PEDIATRICS Vol. 115 No. 6 June 2005 1529 at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from and postnatal age of Ͻ6 hours. Exclusion criteria were the pres- ence of major congenital malformations; hydrops fetalis; persistent pulmonary hypertension of the newborn (PPHN); grade 2 to 4 IVH; platelet count of Ͻ50 000 platelets per mm 3 ; tendency to bleed, as revealed by hematuria, blood in the endotracheal aspi- rate, gastric aspirate, or stools, or oozing from puncture sites; or serum creatinine concentration of Ͼ1.5 mg/dL. Neonates were enrolled after written informed consent was obtained from their parents. Study Design The infants in each unit were assigned randomly to a treatment group with the sealed-envelope technique; envelopes were pre- pared at Careggi University Hospital of Florence and then distrib- uted to participating centers. Each infant received 3 doses of ibuprofen lysine (Arfen; Lisapharma, Erba, Italy; 10 mg/kg within 6 hours after birth, followed by 5 mg/kg after 24 and 48 hours) or indistinguishable placebo. The medications were infused contin- uously in a period of 15 minutes. The doses and dosing intervals were the same as those used for newborn infants in previous studies. 21–23 When the ductus arteriosus was still patent after the randomly assigned treatment for a patient of either group, ibuprofen was administered as a nonrandomized rescue treatment. If this ther- apy also failed to promote ductal closure or if there was a contra- indication to repeated pharmacologic treatment, then surgical li- gation of the ductus arteriosus was performed. Echographic Study All patients for whom study permission was requested under- went cerebral ultrasonography within the first 6 hours of life, to exclude grade 2 to 4 IVH. Serial echoencephalography was per- formed 24 and 48 hours after the first study, on postnatal days 7, 15, and 30, and at 40 weeks’ postconceptional age. The images were obtained with a high-resolution (7.5-MHz), real-time, sector scanner, in both coronal and sagittal projections through the an- terior fontanel. The grading system for hemorrhage was adapted from that described by Papile et al, 32 as follows: grade 1, blood in the periventricular germinal matrix regions or germinal matrix hem- orrhage; grade 2, blood within the lateral ventricular system with- out ventricular dilation; grade 3, blood acutely distending the lateral ventricles; grade 4, blood within the ventricular system and parenchyma. Hemorrhage was considered to have extended if an intraventricular or parenchymal component developed from a germinal matrix hemorrhage or a second hemorrhage was not in the hemisphere opposite that with an existing hemorrhage. The echoencephalographic studies were also evaluated for the pres- ence of periventricular leukomalacia (PVL). All infants identified as having PVL had cystic areas on the 40-week cerebral ultrasound scans; earlier scans of the same infants showed parenchymal echodensities. PVL was graded from grade 1 to grade 3 according to the classification described by De Vries et al. 33 Echocardiographic examinations were performed for all pa- tients before enrollment and on postnatal days 2, 3, 5, 7, and 21 (or more frequently, if indicated). The initial evaluation included 2-dimensional, M-mode, pulsed Doppler and color flow evalua- tions of cardiac flow dynamics, performed to ascertain the nor- mality of cardiac anatomic features and to rule out the possibility of congenital heart disease with “ductus-dependent” pulmonary or systemic blood flow or PPHN. Two-dimensional studies were performed for direct observation of the PDA, and left-to-right shunts were documented with pulsed Doppler echocardiography and color flow mapping. A diagnosis of significant PDA was made with echocardiographic demonstration of a ductal left-to- right shunt, with a left atrium/aortic root ratio of Ͼ1.3 or a ductal size of Ͼ1.5 mm. 21 All echographic studies were performed by physicians who were unaware of the infants’ treatment assign- ments. Concomitant Treatment Daily clinical care was performed by attending physicians, in accordance with common practices. Fluid intake was based essen- tially on changes in body weight, serum electrolyte concentra- tions, and serum osmolality; we started with ϳ70 mL/kg, which was increased 10 to 20 mL each day to reach 150 mL/kg at the end of the first week of life. Infants could receive human milk from donors (and then from their own mothers) from the first day of life. When dextrose infusion was indicated, its concentration was set to maintain appropriate plasma glucose levels. Electrolytes were added after the first day of life, whereas intravenous admin- istration of amino acids and lipids was initiated generally by the second day of life. When hypotension was refractory to fluid-replacement therapy (with plasma, packed red cells, or more rarely saline), dopamine and/or dobutamine infusion was started. For infant respiratory distress syndrome (iRDS), infants received oxygen therapy, respi- ratory support (nasal continuous positive pressure, synchronized mechanical ventilation, or high-frequency oscillatory ventilation), and early rescue surfactant treatment (Curosurf; Chiesi, Parma, Italy; 200 mg/kg plus 100 mg/kg after 12 hours). The objective of assisted ventilation was to maintain an arterial partial pressure of oxygen of 50 to 70 mm Hg, arterial partial pressure of carbon dioxide of Ͻ65 mm Hg, pH of Ͼ7.20, and oxygen saturation of 90% to 95%. Infants who underwent mechanical ventilation, had signs of sepsis, or were predisposed to infection because of maternal fac- tors were given antibiotics after appropriate studies. Antibiotic therapy was stopped after 3 or 4 days if the bacterial cultures (of blood, tracheal aspirate, and urine) remained negative. Postnatal steroid treatment (12 days of tapering doses of dexamethasone 34 ) was started for infants with severe respiratory failure who were receiving maximal ventilatory and oxygen support and for infants who, after 2 weeks of life, were still undergoing mechanical ven- tilation and were considered at high risk of developing chronic lung disease. Clinical Courses and Outcomes For each newborn infant, gestational age, birth weight, gender, type of delivery, Apgar scores at 1 and 5 minutes, pH of umbilical artery blood, prenatal and postnatal steroid treatment, main ma- ternal pregnancy pathologic conditions, length of stay in the hos- pital, and death were recorded. To evaluate the severity of iRDS, initial (at the first blood gas analysis) and highest values of the oxygenation index (mean airway pressure ϫ fraction of inspired oxygen ϫ 100/arterial partial pressure of oxygen) and the venti- latory index (oxygenation index ϫ arterial partial pressure of carbon dioxide) were measured for patients undergoing mechan- ical ventilation. Serum creatinine levels and platelet counts were measured at 1, 3, and 5 days of life. Urine output was measured every day during the first 5 days of life, by collecting urine in adhesive bags, and oliguria was defined as a urinary output of Ͻ1 mL/kg per hour during a 24-hour collection period; fluid intake was recorded every day during the first week of life. To evaluate bleeding tendencies, hematuria, gastric bleeding, blood in the endotracheal aspirate or stools, and oozing from puncture sites were assessed. Our patients were also monitored for complications such as sepsis, bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity (ROP). Diagnoses of sepsis were based on clinical and laboratory data (total neutrophil counts, immature/total neutrophil ratios, and C-reactive protein concen- trations) and confirmed with positive blood cultures. 35 Diagnosis of bronchopulmonary dysplasia was based on the requirement for supplemental oxygen to maintain adequate oxygenation at 36 weeks’ postconceptional age. 36 Necrotizing enterocolitis was diagnosed in the presence of abdominal distension, gastric resid- uals with or without bile-stained vomiting and bloody diarrhea or stools, hypotension, and suggestive abdominal radiographs (showing dilated and thickened bowel loops, parietal pneumatosis with or without perforation, or portal or hepatic venous air). 37 The incidence of ROP, staged according to the international classifica- tion, 38 was also recorded. All clinical and biological data were reported on data sheets designed for this study. Statistical Analyses In our study, we considered as successful outcomes grade 1 IVH or no IVH at 7 days of life, whereas grade 2 to 4 IVH represented failure. We assumed a failure rate 20% higher in the placebo group than in the ibuprofen group. Therefore, at a power of 0.80 and ␣ ϭ .05, the estimated sample size was 74 infants in each group. Clinical characteristics of the 2 groups were described with 1530 IBUPROFEN AND IVH at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from mean values and SDs or rates and percentages. Statistical analyses were performed with Student’s t test for parametric continuous variables, the 2-sample Wilcoxon rank-sum test for nonparametric continuous variables, and Fisher’s exact test for categorical vari- ables such as frequencies. P Ͻ .05 was considered statistically significant. Multiple stepwise logistic regressions were conducted to deter- mine which maternal, neonatal, or perinatal factors would influ- ence the risk for development of grade 2 to 4 IVH. Effect estimates are expressed as odds ratios (ORs) with profile, likelihood-based, 95% confidence intervals (CIs). RESULTS Two hundred fifty patients were eligible for the study, but 80 were excluded because of the presence of cardiac malformations (n ϭ 4), hydrops fetalis (n ϭ 3), PPHN (n ϭ 15), grade Ն2 IVH (n ϭ 20), platelet counts of Ͻ50 000 platelets per mm 3 or bleeding tendency (n ϭ 25), or serum creatinine concentra- tions of Ͼ1.5 mg/dL (n ϭ 13). Among the remaining 170 infants, 10 were excluded because of a lack of parental consent and 5 were excluded after random- ization because of incomplete data collection (4 in the ibuprofen group and 1 in the placebo group). There- fore, we studied 155 infants, 77 of whom were as- signed to the ibuprofen group and 78 to the placebo group. The initial dose of the drug was administered at 5.2 Ϯ 0.6 hours and 5.4 Ϯ 0.5 hours in the ibupro- fen and placebo groups, respectively. The groups had comparable proportions of maternal and obstet- ric factors (Table 1); they were also comparable in clinical characteristics except for gestational age (Ta- ble 2). The proportions of infants with grade 1 IVH at enrollment were similar in the ibuprofen (n ϭ 4, 5%) and placebo (n ϭ 5, 6%) groups. Two of these infants in each group experienced progression of hemor- rhage; the 2 infants in the ibuprofen group devel- oped grade 2 IVH, whereas 1 infant in the placebo group developed grade 2 IVH and another devel- oped grade 3 IVH. Grade 2 to 4 IVH developed for 21% of the ibuprofen-treated infants and for 17% in the placebo group (Table 3). The incidences of grade 1, grade 2, grade 3, and grade 4 IVH were similar in the ibuprofen and placebo groups. We considered the possibility that the occurrence of IVH could differ between the groups at different times. For this rea- son, we compared the IVH rates at baseline and at 24 hours, 48 hours, and 7 days of life, but we did not find any difference between the ibuprofen group and the placebo group (Table 4). The infant survival rates were similar in the 2 groups (Table 5). The most frequent causes of death were refractory respiratory failure and sepsis. There was no significant difference between the groups in the occurrence of iRDS or its severity, the require- ment for or type of mechanical ventilation, or the need for surfactant treatment (Table 2). The rates of sepsis, bronchopulmonary dysplasia, necrotizing en- terocolitis, ROP (all grades), and PVL (all grades) and the lengths of stay in the hospital were similar in the ibuprofen and placebo groups (Table 5). The occurrence of PDA was less frequent on day 3 of life in the ibuprofen group (Table 5). The incidences of serum creatinine levels of Ͼ1.5 mg/dL, mean serum creatinine levels, urine outputs, rates of oliguria, bleeding tendency, and platelet counts of Ͻ50 000/ mm 3 , and mean platelet counts did not differ be - tween the ibuprofen and placebo groups (Table 5). Logistic-regression analysis included all variables in Tables 1 and 2 and also the occurrence of grade 1 IVH at enrollment, bleeding tendency, thrombocyto- penia, and PDA in the day 3 of life. We found that the following factors had significant predictive val- ues for the development of grade 2 to 4 IVH: male gender (OR: 2.3; 95% CI: 1.76–2.84) and prenatal steroid treatment (OR: 0.30; 95% CI: Ϫ1.66 to Ϫ0.71). DISCUSSION The anomalies of cerebral perfusion play an im- portant role in the development of cerebral injury among preterm infants. Prostaglandins, especially prostaglandin E 2 and F 2 ␣ , are determinants in the control of the upper range of CBF autoregulation; they exert a minimal vasoconstrictor activity, which could prevent an increase in CBF when systemic blood pressure increases. 30 Ibuprofen was reported to enhance CBF autoregulation among newborn pig- lets, 30 and Li et al 39 demonstrated that its effect was secondary to the up-regulation of prostaglandin E 2 and F 2 ␣ receptors induced by inhibition of the isoen - zyme cyclooxygenase-2. Therefore, with stabilization of cerebral perfusion, a reduction in the incidence of IVH among preterm infants might be expected. Varvarigou et al 21 reported a trend toward a de - crease in the incidence of IVH among preterm in- fants, although this was not statistically significant and was not confirmed in other studies. 39 Unfortunately, our study demonstrated that ibu- profen was ineffective in preventing grade 2 to 4 IVH, confirming the results of a recent meta-analysis study of the prevention of PDA with ibuprofen pro- phylaxis. 40 This result suggests that the action of ibuprofen in improving CBF autoregulation among preterm infants is insufficient to limit brain injuries. We wondered why ibuprofen is ineffective in reduc- TABLE 1. Comparison Between Ibuprofen and Placebo Groups in Obstetric and Maternal Factors Ibuprofen (n ϭ 77) Placebo (n ϭ 78) Cesarean delivery, rate (%) 42/77 (55) 56/78 (72) Prenatal steroids, rate (%) 56/77 (73) 58/78 (74) No. of cycles, mean Ϯ SD 1.1 Ϯ 0.3 1.3 Ϯ 0.8 Preterm noninduced labor, rate (%) 46/77 (60) 58/78 (74) Preeclampsia, rate (%) 24/77 (31) 16/78 (21) Preterm premature rupture of membranes, rate (%) 6/77 (8) 6/78 (8) Gestational diabetes mellitus, rate (%) 3/77 (4) 5/78 (6) Abruptio placentae, rate (%) 8/77 (10) 6/78 (8) ARTICLES 1531 at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from TABLE 2. Comparison Between Ibuprofen and Placebo Groups in Neonatal Factors Ibuprofen (n ϭ 77) Placebo (n ϭ 78) Birth weight, g, mean Ϯ SD 832 Ϯ 215 812 Ϯ 209 Gestational age, wk, mean Ϯ SD 25.3 Ϯ 1.2 25.9 Ϯ 1.1* Male/female, n 50/27 32/46 Apgar score, mean Ϯ SD 1 min 4.2 Ϯ 2.3 4.8 Ϯ 2.2 5 min 6.6 Ϯ 2.2 7.0 Ϯ 1.6 pH of umbilical artery blood, mean Ϯ SD 7.28 Ϯ 0.11 7.29 Ϯ 0.11 Respiratory diseases Rate (%) 75/77 (97) 75/78 (96) iRDS, rate (%) 70/75 (93) 71/75 (95) Transient tachypnea of the newborn, rate (%) 5/75 (7) 4/75 (5) Oxygen therapy Rate (%) 74/77 (96) 75/78 (96) Duration, d, mean Ϯ SD 40.9 Ϯ 33.1 42.6 Ϯ 35.2 Mechanical ventilation SIMV/SIPPV, rate (%) 57/77 (74) 53/78 (68) HFOV, rate (%) 26/77 (34) 17/78 (22) Duration, h, mean Ϯ SD 397.6 Ϯ 426.7 339.0 Ϯ 347.1 Surfactant Rate (%) 57/77 (74) 50/78 (64) Age at treatment, min, mean Ϯ SD 63.3 Ϯ 47.7 79.5 Ϯ 75.8 No. of doses, mean Ϯ SD 1.8 Ϯ 0.9 2.1 Ϯ 1.3 Oxygenation index Initial value, mean Ϯ SD 6.8 Ϯ 7.8 7.3 Ϯ 8.5 Highest value, mean Ϯ SD 10.9 Ϯ 12.3 12.3 Ϯ 14.5 Age at highest value, h, mean Ϯ SD 28.1 Ϯ 97.6 31.0 Ϯ 69.2 Ventilatory index Initial value, mean Ϯ SD 257.0 Ϯ 246.1 232.9 Ϯ 167.0 Highest value, mean Ϯ SD 389.6 Ϯ 326.5 365.2 Ϯ 300.3 Age at highest value, h, mean Ϯ SD 29.6 Ϯ 99.1 35.1 Ϯ 68.6 Total or partial parenteral nutrition, rate (%) 67/77 (87) 70/78 (90) Fluid intake, mL/kg, mean Ϯ SD DOL 1 65.9 Ϯ 12.2 65.7 Ϯ 17.9 DOL 2 78.8 Ϯ 13.9 83.1 Ϯ 17.6 DOL 3 98.5 Ϯ 14.9 107 Ϯ 34.9 DOL 4 121.8 Ϯ 19.5 122.5 Ϯ 36.7 DOL 5 138.9 Ϯ 24.1 134.7 Ϯ 27.9 DOL 6 147.9 Ϯ 23.3 146.6 Ϯ 21.5 DOL 7 156.5 Ϯ 21.9 154.5 Ϯ 24.9 Vasoactive drugs Rate (%) 38/77 (49) 37/77 (48) Dopamine, rate (%) 37/38 (97) 37/37 (100) Dopamine duration, d, mean Ϯ SD 10.3 Ϯ 9.9 8.0 Ϯ 7.9 Dobutamine, rate (%) 18/38 (47) 27/37 (73) Dobutamine duration, d, mean Ϯ SD 6.4 Ϯ 1.8 7.0 Ϯ 6.5 PRC transfusions PRCs transfused during week 1, rate (%) 49/77 (64) 48/78 (62) No. of PRC transfusions, mean Ϯ SD 1.7 Ϯ 0.7 1.8 Ϯ 0.9 Plasma transfusions Plasma transfused during week 1, rate (%) 25/77 (32) 23/78 (29) No. of plasma transfusions, mean Ϯ SD 1.7 Ϯ 1.1 1.9 Ϯ 1.5 Postnatal steroid treatment Rate (%) 28/77 (36) 27/78 (35) Duration, d, mean Ϯ SD 12.8 Ϯ 14.7 10.3 Ϯ 9.0 PRC indicates packed red cell; DOL, day of life; SIMV, synchronized intermittent mandatory ventilation; SIPPV, synchronized intermit- tent positive pressure ventilation; HFOV, high-frequency oscillatory ventilation. * P ϭ .001, placebo group versus ibuprofen group. TABLE 3. Comparison of Incidence of IVH at 7 Days of Life Rate (%) P OR (95% CI) Ibuprofen (n ϭ 77) Placebo (n ϭ 78) Successful outcome (no IVH or grade 1) 61 (79) 65 (83) .652 0.865 (0.387–1.932) Grade 1 4 (5) 6 (8) .760 1.476 (0.761–5.390) Grade 2 8 (10) 5 (6) .562 0.661 (0.206–2.117) Grade 3 6 (8) 5 (6) .982 0.856 (0.253–2.898) Grade 4 2 (3) 3 (4) .972 1.500 (0.227–9.225) Grade 2–4 16 (21) 13 (17) .652 0.866 (0.246–3.050) Total IVH 20 (26) 19 (24) .963 0.963 (0.475–2.034) 1532 IBUPROFEN AND IVH at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from ing the occurrence of IVH whereas indomethacin, which is also a cyclooxygenase inhibitor, is effec- tive. 6–10 We found that several authors observed de - creased CBF after indomethacin administration, both in newborn animals 12,41 and among newborn in - fants, 25,42 but not after ibuprofen treatment. 12,25,42,43 Therefore, we concluded that indomethacin can af- fect cerebral circulation through mechanisms differ- ent from cyclooxygenase blockade and prostaglan- din synthesis, 43 such as direct action on vascular endothelium 44 and the increase in the circulating level of endothelins, 45 which likely can explain also the more frequent occurrence of adverse effects after indomethacin treatment, rather than after ibuprofen treatment. In other words, it is probable that the ineffectiveness of ibuprofen in preventing grade 2 to 4 IVH and the lower occurrence of adverse effects after its administration are secondary to more-selec- tive inhibition of cyclooxygenase isoforms, com- pared with indomethacin, which permits the closure of PDA but is not sufficient to compensate for inad- equate CBF autoregulation among preterm infants. Another possible explanation is that we used an inadequate ibuprofen dose. However, it is difficult to suggest increasing this dose, because in a previous study 21 it was found to be associated with a plasma ibuprofen level 2.5-fold higher than that generated among adults with arthritis receiving similar doses 46 and there are no studies of ibuprofen pharmacoki- netics among newborn infants. In the present study, we monitored the possible adverse effects of ibuprofen treatment, in particular on renal function and the clotting system, but we did not find any difference between the ibuprofen and placebo groups. This confirms previous studies, 40 except that Van Overmeire et al 24 found serum cre - TABLE 4. Comparison of Rates of IVH Before Ibuprofen Ad- ministration, at 24 and 48 Hours, and at 7 Days of Life IVH Rate (%) Before Ibuprofen 24h 48h 7d Grade 1 Ibuprofen 4 (5) 4 (5) 4 (5) 4 (5) Placebo 5 (6) 6 (8) 6 (8) 6 (8) Grade 2 Ibuprofen 0 (0) 6 (8) 7 (9) 8 (10) Placebo 0 (0) 4 (5) 5 (6) 5 (6) Grade 3 Ibuprofen 0 (0) 4 (5) 6 (8) 6 (8) Placebo 0 (0) 4 (5) 5 (6) 5 (6) Grade 4 Ibuprofen 0 (0) 1 (1) 2 (3) 2 (3) Placebo 0 (0) 2 (3) 2 (3) 3 (4) Grade 2–4 Ibuprofen 0 (0) 11 (14) 15 (19) 16 (21) Placebo 0 (0) 10 (13) 12 (15) 13 (17) Total IVH Ibuprofen 4 (5) 15 (19) 19 (25) 20 (26) Placebo 5 (6) 16 (21) 18 (23) 19 (24) TABLE 5. Markers of Potential Adverse Effects and Complications in the Ibuprofen and Placebo Groups Ibuprofen (n ϭ 77) Placebo (n ϭ 78) Serum creatinine level of Ͼ1.5 mg/dL, rate (%) 3/77 (4) 2/77 (3) Serum creatinine level, mg/kg, mean Ϯ SD DOL 1 0.78 Ϯ 0.23 0.77 Ϯ 0.27 DOL 3 1.11 Ϯ 0.39 1.1 Ϯ 0.47 DOL 5 1.09 Ϯ 0.34 0.99 Ϯ 0.33 Oliguria, rate (%) 7/77 (9) 4/78 (5) Urine output, mL/kg per h, mean Ϯ SD DOL 1 1.7 Ϯ 0.9 1.8 Ϯ 1.2 DOL 2 2.8 Ϯ 1.6 2.5 Ϯ 1.3 DOL 3 2.9 Ϯ 1.3 2.9 Ϯ 1.1 DOL 4 3.0 Ϯ 1.4 2.9 Ϯ 1.2 DOL 5 2.8 Ϯ 1.4 3.1 Ϯ 1.2 Bleeding tendency, rate (%) 11/77 (14) 18/78 (23) Platelet counts of Ͻ50 000/mm 3 , rate (%) 8/77 (10) 6/78 (8) Platelet counts, platelets ϫ 10 9 /L, mean Ϯ SD DOL 1 227 627 Ϯ 93 712 205 802 Ϯ 78 568 DOL 3 218 047 Ϯ 101 750 216 303 Ϯ 199 950 DOL 5 224 471 Ϯ 94 323 195 966 Ϯ 148 685 PDA, rate (%) DOL 1 57/77 (74) 56/78 (72) DOL 3 7/77 (9) 23/78 (29)* DOL 5 3/77 (4) 4/78 (5) DOL 21 1/77 2/78 Reopening 1/77 1/78 Surgical ligature 0/77 1/78 Sepsis, rate (%) 15/77 (19) 5/78 (6) Bronchopulmonary dysplasia, rate (%) 16/77 (21) 22/28 (28) Necrotizing enterocolitis, rate (%) 2/78 (3) 2/78 (3) ROP, rate (%) All grades 32/77 (42) 27/78 (35) Grade Ն2 6/32 (19) 6/27 (22) PVL (all grades), rate (%) 3/77 (4) 4/78 (5) Death, rate (%) 15/77 (19) 20/78 (26) Stay in hospital, d, mean Ϯ SD 82.7 Ϯ 21.9 86.9 Ϯ 23.1 DOL indicates day of life. * P ϭ .0019 for placebo group versus ibuprofen group. ARTICLES 1533 at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from atinine levels to be increased on day 3 of life among ibuprofen-treated infants. The recorded complica- tions of prematurity also showed similar rates in the 2 groups, except for the incidences of PDA on day 3 of life (9% in the treated group and 29% in the placebo group), which confirmed that prophylactic treatment with ibuprofen reduced PDA occurrence among preterm infants with iRDS at 3 days of life. 23 However, among patients in the placebo group who demonstrated PDA at 3 days of life, 83% (19 of 23 patients) experienced closure of the ductus arteriosus after the first cycle of ibuprofen, as reported previ- ously. 19,23,24 A final issue in our study was the possible occur- rence of PPHN among our patients after ibuprofen administration, as reported by Gournay et al. 47 None of our patients demonstrated PPHN 47 after ibupro - fen treatment; we think this was because all infants with PPHN were excluded from the study. In fact, it is our opinion that the reported PPHN was preexist- ing, not caused by ibuprofen, and that PDA closure only worsened and manifested it. CONCLUSIONS Our study demonstrated that prophylactic ibupro- fen was ineffective in preventing grade 2 to 4 IVH and its use for this purpose cannot be recommended. We confirmed that ibuprofen therapy for PDA clo- sure is safe and effective. Because ibuprofen cannot represent an alternative to indomethacin and indo- methacin treatment might be followed by several adverse effects, the question of pharmacologic IVH prevention among preterm infants remains crucial and additional efforts are necessary to identify other potentially effective drugs. ACKNOWLEDGMENTS The IntraVentricular Ibuprofen Study Group includes G.L. Lista, MD (Milan, Italy); Hubert Messner, MD (Bolzano, Italy); Fabio Mosca, MD (Milan, Italy); and Paolo Tagliabue, MD (Monza, Italy). REFERENCES 1. Rubaltelli FF, Dani C, Reali MF, et al. Acute neonatal respiratory dis- tress in Italy: a one year prospective study. Acta Paediatr. 1998;87: 1261–1268 2. Krishnamooorthy KS, Shannon DC, DeLong GR, Todres ID, Davis KR. Neurologic sequelae in the survivors of neonatal intraventricular hem- orrhage. Pediatrics. 1979;64:233–237 3. Shinnar S, Molteni RA, Gammon K, D’Souza BJ, Altman J, Freeman JM. Intraventricular hemorrhage in the premature infant. N Engl J Med. 1982;306:1464–1468 4. McMenamin JB, Shackelford GD, Volpe JJ. Outcome of neonatal intra- ventricular hemorrhage with periventricular echodense lesions. Ann Neurol. 1984;15:285–290 5. Szymonowicz W, Yu VYH, Bajuk B, Astbury J. Neurodevelopmental outcome of periventricular hemorrhage and leukomalacia in infants 1250 g or less at birth. Early Hum Dev. 1986;14:1–7 6. Banstra ES, Montalvo BM, Goldberg RN. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pedi- atrics. 1984;74:1107–1112 7. Bada HS, Green RS, Pourcyrous M, et al. Indomethacin reduced the risks of severe intraventricular hemorrhage. J Pediatr. 1989;115:631–637 8. Ment LR, Duncan CC, Ehrenkrnaz RA. Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr. 1985;107:937–943 9. Ment LR, Oh W, Ehrenkrnaz RA, et al. Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. Pediatrics. 1994;93:543–550 10. Fowlie PW, Davis PG. Prophylactic intravenous indomethacin for pre- venting mortality and morbidity in preterm infants. Cochrane Database Syst Rev. 2002;(3):CD000174 11. Leffler CW, Busija DW, Fletcher AM, Beasley DG, Hessler JR, Green RS. Effects of indomethacin upon cerebral hemodynamics of newborn pigs. Pediatr Res. 1985;19:1160 –1164 12. Chemtob S, Beharry K, Barna T, Varma DR, Aranda JV. Difference in the effects in the newborn piglet of various non-steroidal anti-inflammatory drugs on cerebral blood flow but not on cerebrovascular prostaglan- dins. Pediatr Res. 1991;30:106–111 13. Dahlgren N, Nilsson B, Sakabe T. The effect of indomethacin on cerebral blood flow and oxygen consumption in the rat at the normal and increased carbon dioxide tension. Acta Physiol Scand. 1982;3:475– 485 14. Ment LR, Stewart WB, Ardito TA, Huang E, Madri JA. Indomethacin promotes germinal matrix microvessel maturation in the newborn bea- gle pup. Stroke. 1992;23:1132–1137 15. Betkerur MV, Yeh TF, Miller K, Glasser RJ, Pildes RS. Indomethacin and its effects on renal function and urinary kallikrein excretion in prema- ture infants with patent ductus arteriosus. Pediatrics. 1981;68:99 –102 16. Van Bel F, Guit GL, Schipper J, Van de Bor M, Baan J. Indomethacin- induced changes in renal blood flow velocity waveform in premature infants investigated with color Doppler imaging. J Pediatr. 1991;118: 621–626 17. Grosfeld JL, Chaedt M, Molinari F. Increased risk of necrotizing entero- colitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg. 1996;224:350–357 18. Ojala R, Ikonen S, Tammela O. Perinatal indomethacin treatment and neonatal complications in preterm infants. Eur J Pediatr. 2000;159: 153–155 19. Lago P, Bettiol T, Salvadori S, et al. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomized control trial. Eur J Pediatr. 2002;161:202–207 20. Coceani F, White E, Bodach E, Olley PM. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen. Can J Physiol Pharmacol. 1979;57:825–831 21. Varvarigou A, Bardin LC, Beharry K, Chemtob S, Papageorgiu A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA. 1996;275:539 –544 22. Van Overmeire B, Follens I, Hartmann S, Creten WL, van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child. 1997;76:F179–F184 23. Dani C, Bertini G, Reali MF, et al. Prophylaxis of patent ductus arteri- osus with ibuprofen in preterm infants. Acta Paediatr. 2000;89:1369–1374 24. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibupro- fen and indomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000;343:674 – 681 25. Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effect of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arte- riosus. J Pediatr. 1997;131:549–554 26. Mosca F, Bray M, Colnaghi MR, Fumagalli M, Compagnoni G. Cerebral vasoreactivity to arterial carbon dioxide tension in premature infants: effect of ibuprofen. J Pediatr. 1999;135:644–646 27. Grosfeld JL, Kamman K, Gross K, Cikrit D, Ross D, Wolfe M. Compar- ative effects of indomethacin, prostaglandin E 1 and ibuprofen on bowel ischemia. Pediatr Surg. 1983;18:738–742 28. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr. 1999;135:733–738 29. Malcom DD, Segar JL, Robillard E, Chemtob S. Indomethacin compro- mises hemodynamics during positive-pressure ventilation indepen- dently of prostanoids. J Appl Physiol. 1993;74:1672–1678 30. Chemtob S, Beharry K, Barna T, Varma DR, Aranda JV. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets. Stroke. 1990;21:777–784 31. Chemtob S, Roy M-S, Abran D, Ferandez H, Varma DR. Prevention of post-asphyxial increase in lipid peroxides and retinal function deterio- ration in the newborn pig by inhibition of cyclooxygenase activity and free radical generation. Pediatr Res. 1993;33:336–340 32. Papile LA, Burstein J, Burstein R, Keffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birthweight less than 1500 grams. J Pediatr. 1978;92:529 –534 33. De Vries LS, Eken P, Dubowitz LM. The spectrum of leukomalacia using cranial ultrasounds. Behav Brain Res. 1992;49:1– 6 34. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes PS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in sur- factant-treated infants. Pediatrics. 1996;98:204–210 1534 IBUPROFEN AND IVH at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from 35. American Academy of Pediatric, Committee on Drugs, Committee on Fetus and Newborn, and Committee on Infectious Diseases. Prophy- laxis and treatment of neonatal gonococcal infections. Pediatrics. 1980; 65:1047–1048 36. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82:527–532 37. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, Brotherton T. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg. 1978;187:1–12 38. Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthal- mol. 1984;102:1130 –1134 39. Li DY, Hardy P, Abran D, et al. Key role for cyclooxygenase-2 in PGE 2 and PGF 2 ␣ receptor regulation and cerebral blood flow of the newborn. Am J Physiol. 1997;273:R1283–R1290 40. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2003;(2):CD004213 41. Pappius HM, Wolfe LS. Effects of indomethacin and ibuprofen on cerebral metabolism and blood flow in traumatized brain. J Cereb Blood Flow Metab. 1983;3:448 – 459 42. Patel J, Robert I, Azzopardi D, Hamilton P, Edwards AD. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res. 2000;47:36–42 43. Pellicer A, Aparicio M, Cabanas F, Valverde E, Quero J, Stiris TA. Effects of the cyclo-oxygenase blocker ibuprofen on cerebral blood flow during normocarbia and hypercarbia in newborn piglets. Acta Paediatr. 1999;88:82–88 44. Siesjo BK. Cerebral circulation and metabolism. J Neurosurg. 1984;60: 883–908 45. Therkelsen K, Jensen KA, Freundlich M, Thorshange H, Bunemann L, Bogeskov-Nielsen L. Endothelin-1 and cerebral blood flow: influ- ence of hypoxia, hypercapnia, and indomethacin on circulating en- dothelin levels in healthy volunteers. Scand J Clin Lab Invest. 1994; 54:441–451 46. Gallo JM, GalI IP, Gillespie WR, Albert KS, Perrier D. Ibuprofen kinetics in plasma and synovial fluid of arthritic patients. J Clin Pharmacol. 1986;26:65–70 47. Gournay V, Savagner C, Thiriez G, Kuster A, Roze´ JC. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lan- cet. 2002;259:1486 –1488 WHILE BRAIN IMAGING OFFERS NEW KNOWLEDGE, IT CAN BE AN ILLUSION “There, right there, see that spot of blazing red in a cool blue sea of your cortex? That’s your brain on drugs. Or, more specifically, that’s the brain of a recovering cocaine addict, clean for months, who sees a mound of white powder. His brain responds with the same craving and anxiety—marked by the red on the brain scan—as when he was snorting every night, which is why addiction is so tenacious. And here, see how a chess grandmaster activates the region of the brain that stores memories, such as those of games he has played or studied? But in the brain of a neophyte the activity is over here, in a region that analyzes positions from scratch Neuroimaging such as PET and MRI are seducing laypeople and scientists alike into believing we know more than we do about how and why we think, feel and behave, some scientists say. The power of brain imaging, says Frank Keil, a Yale University psychology professor, reflects ‘the illusion of ex- planatory depth. If people see something, they are often deluded into thinking they understand it better than they really do.’ In a fit ofphysics envy, researchers in economics, political science and even philosophy are deciding that neuroimag- ing is just the thing to make them more scientific. Yet the results are less than groundbreaking Forallitsflaws, neuroimaging is here to stay. No self-respect- ing psych department can afford to forgo it.” Begley S. Wall Street Journal. 2005 Noted by JFL, MD ARTICLES 1535 at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from DOI: 10.1542/peds.2004-1178 2005;115;1529Pediatrics Martano and Firmino F. Rubaltelli Carlo Dani, Giovanna Bertini, Marco Pezzati, Chiara Poggi, Pietro Guerrini, Claudio Among Preterm Infants: A Multicenter, Randomized Study Prophylactic Ibuprofen for the Prevention of Intraventricular Hemorrhage Services Updated Information & tml http://pediatrics.aappublications.org/content/115/6/1529.full.h including high resolution figures, can be found at: References tml#ref-list-1 http://pediatrics.aappublications.org/content/115/6/1529.full.h at: This article cites 42 articles, 10 of which can be accessed free Citations tml#related-urls http://pediatrics.aappublications.org/content/115/6/1529.full.h This article has been cited by 3 HighWire-hosted articles: Subspecialty Collections orn_infant_sub http://pediatrics.aappublications.org/cgi/collection/fetus:newb Fetus/Newborn Infant the following collection(s): This article, along with others on similar topics, appears in Permissions & Licensing ml http://pediatrics.aappublications.org/site/misc/Permissions.xht tables) or in its entirety can be found online at: Information about reproducing this article in parts (figures, Reprints http://pediatrics.aappublications.org/site/misc/reprints.xhtml Information about ordering reprints can be found online: rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275. Grove Village, Illinois, 60007. Copyright © 2005 by the American Academy of Pediatrics. All and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk publication, it has been published continuously since 1948. PEDIATRICS is owned, published, PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly at Viet Nam:AAP Sponsored on February 11, 2014pediatrics.aappublications.orgDownloaded from